US7538129B2 - Diazonamide A analog - Google Patents

Diazonamide A analog Download PDF

Info

Publication number
US7538129B2
US7538129B2 US11/591,016 US59101606A US7538129B2 US 7538129 B2 US7538129 B2 US 7538129B2 US 59101606 A US59101606 A US 59101606A US 7538129 B2 US7538129 B2 US 7538129B2
Authority
US
United States
Prior art keywords
compound
added
cells
paclitaxel
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related, expires
Application number
US11/591,016
Other languages
English (en)
Other versions
US20070149583A1 (en
Inventor
Patrick G. Harran
Noelle Williams
Anthony Burgett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/264,502 external-priority patent/US7517895B2/en
Application filed by University of Texas System filed Critical University of Texas System
Priority to US11/591,016 priority Critical patent/US7538129B2/en
Assigned to BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM reassignment BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BURGETT, ANTHONY, HARRAN, PATRICK G., WILLIAMS, NOELLE
Publication of US20070149583A1 publication Critical patent/US20070149583A1/en
Assigned to NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT reassignment NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT CONFIRMATORY LICENSE (SEE DOCUMENT FOR DETAILS). Assignors: UNIVERSITY OF TEXAS SW MEDICAL CENTER AT DALLAS
Application granted granted Critical
Publication of US7538129B2 publication Critical patent/US7538129B2/en
Assigned to NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR reassignment NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR CONFIRMATORY LICENSE (SEE DOCUMENT FOR DETAILS). Assignors: UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
Assigned to NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR reassignment NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR CONFIRMATORY LICENSE (SEE DOCUMENT FOR DETAILS). Assignors: UT SOUTHWESTERN MEDICAL CENTER
Expired - Fee Related legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the invention relates to an analog of diazonamide A that has superior antitumor activity.
  • a synthetic route to this compound is also disclosed.
  • Diazonamide A is a mitotic spindle-disrupting agent first isolated from the marine organism Diazona angulata . Numerous attempts have been made to synthesize this compound and its analogs.
  • PCT publication WO 03/106438 describes a putative synthetic route; however, the structure of diazonamide A provided in that publication is incorrect.
  • U.S. Pat. No. 7,022,720 ('720) correctly discloses the structure of diazonamide A and describes the synthesis of some of its analogs through the combined use of catalytic Heck endocyclization, stereo-controlled ring-contracting pinnacol rearrangement, and indole arylation via internal photo-induced electron transfer. Generic structures of some analogs are provided.
  • a daughter application claiming priority from this patent was filed 31 Oct. 2005 and is published as 2006/0089397 and includes the structure of the analog, Compound J, claimed herein.
  • the '720 patent does not specifically describe the compound of the present invention, which has surprisingly potent anti-mitotic activity
  • the present invention is directed to a compound of the formula
  • Compound J Compound J and the pharmaceutically acceptable salts thereof.
  • the invention is also directed to pharmaceutical compositions containing this compound and/or its salts, to modified forms of this compound coupled to stabilizing or targeting agents, and to methods of treating proliferative diseases, in particular TaxolTM-resistant cancers, using these compounds and formulations.
  • the invention is directed to methods to synthesize Compound J and its salts.
  • FIG. 1 shows the ability of Compound J to inhibit the growth of various cancer cell lines in comparison to diazonamide A, a hydroxylated form of Compound J., paclitaxel, and vinblastine.
  • FIG. 2 shows a plot of survival fraction against concentration of drug with respect to PTX10 ovarian cancer cell lines for Compound J and paclitaxel.
  • FIG. 3 is a graph showing the pharmacokinetics of Compound J.
  • FIGS. 4A and 4B show the effect of Compound J as compared to paclitaxel on xenografts of HCT116 and PC-3 cells.
  • FIGS. 5A and 5B show that Compound J has no effect on neutrophil proliferation or cell counts in vivo.
  • Compound J has been shown, as described in the examples below, to have potent anti-mitotic activity with respect to certain cancers, in particular cancers that are resistant to TaxolTM.
  • Compound J can be supplied in its free base form, or can be supplied as a pharmaceutically acceptable salt, or as a mixture of the depicted form and the corresponding salt.
  • Suitable salts include those of inorganic acids such as hydrochlorides, hydrobromides, sulfates, hydrosulfates, and the like, or organic acid addition salts such as the acetates, formates, maleates, and the like.
  • Compound J may be coupled to moieties such as targeting agents.
  • targeting agents are antibodies or immunologically active fragments thereof, including single-chain antibody forms directed against tumor antigens or against receptors or integrins associated with tumors, peptidomimetics directed against these moieties, and the like.
  • Compound J may be coupled to an excipient such as polyethylene glycol for altering pharmacokinetics.
  • formulations useful in the invention include standard formulations such as those set forth in Remington's Pharmaceutical Sciences , latest edition, Mack Publishing Co., Easton, Pa., incorporated herein by reference. Such formulations include those designed for oral delivery, slow release, topical administration, parenteral administration, or any other suitable route as determined by an attending physician or veterinarian. Thus administration may be systemic or local. Suitable vehicles or excipients include liposomes, micelles, nanoparticles, polymeric matrices, buffers, and the full range of formulations known to practitioners.
  • Compound J is particular useful in treating proliferative diseases, in particular, tumors and malignancies associated with breast, ovary, lung, colon, prostate, melanoma, colon, pancreas, glioma, carcinoma, and the like.
  • compositions that include Compound J and/or its salt and/or its conjugates may also be used in combination with other drugs, such as additional antitumor agents or other palliative compounds such as compounds that aid in nutrition or general health.
  • Compound J is conveniently synthesized by treating the free amino precursor with S-2,5-dioxopyrrolidin-1-yl-2-hydroxy-3-methylbutanoate. This converts the free amine to the 3-methyl-2-hydroxybutylate.
  • this coupling reaction can also be accomplished with other activated esters of the 2-hydroxy3-methylbutanoate, such as by way of example only N-hydroxybenzotriazole ester, perfluorophenyl ester, N-hydroxyphthalimide esters, activated esters generated by the reaction of the carboxylic acid with a carbodiimide, and other activated esters conventionally used for acylation of an amine to form amide bonds; thus the invention provides a method to prepare Compound J by coupling an activated 2-hydroxy-3-methylbutanoate derivative, which may optionally be protected at the 2-hydroxyl, with the above described amine.
  • the amine may also optionally be in protected form, i.e.
  • Suitable protecting groups for use on the hydroxyl include acyl groups, silyl groups, pyran acetals, and the like.
  • Suitable protecting groups for use on the ring nitrogen atoms of the amine compound, which are not intended to react with the hydroxybutanoate activated ester may include acyl groups such as carbamates or trifluoroacetate, as well as silyl groups. Suitable protecting groups and methods to attach and remove them are well known in the art, and are described, for example, in T. H. Greene, P ROTECTIVE G ROUPS IN O RGANIC S YNTHESIS , 2 nd ed.
  • Examples 1-16 describe the synthesis of Compound J.
  • Examples 17-20 describe its biological activity.
  • Example 3 The title compound of Example 3 (256.6 g, 770 mmol), TBTU (296.4 g, 1.2 eq) and Cbz-L-valine (212.7 g, 1.1 eq) were dissolved in dimethylformamide (DMF, anhydrous, 2,700 mL) and cooled to 0° C. for 30 min. Diisopropylethylamine (DIEA, 268 mL) was added slowly and the solution was allowed to warm to room temperature. Stirring was continued for 4 hours at which time HPLC indicated completion of reaction. The reaction was diluted with ethyl acetate (11 L) and water (7.5 L). The mixture was stirred for 1 hour and allowed to separate.
  • DIEA dimethylformamide
  • the organic layer was washed once with water (7.5 L), twice with brine (7.5 L) and twice with saturated NaHCO 3 (7.5 L).
  • the material was dried with sodium sulfate and concentrated to brown black solid.
  • the material was taken up in methylene chloride (7.5 L) and combined with 22.2 g of another lot of similar quality material and silica gel (400 g). The solvent was removed to support the crude compound on silica. This material was divided in half and each half was chromatographed on a 6 in ⁇ 4 ft silica gravity column.
  • Example 7 The title compound of Example 7 (45.0 g, 65 mmol) was dissolved in tetrahydrofuran (325 mL) and was added rapidly to a ⁇ 20° C. solution of PhI(OAc) 2 (20 g, 62 mmol) and LiOAc (12.7 g, 196 mmol) in 2,2,2-trifluoroethanol (13.0 L). The solution was stirred at ⁇ 20° C. for 25 minutes at which time solid NaHCO 3 (117.5 g) was added. The cold bath was removed and stirring was continued for an additional 30 min. The mixture was filtered at 10° C. and the filtrate was concentrated.
  • Example 8 To a flask containing the compound synthesized in Example 8 (102 mg, 0.148 mmol) was added methanol (3.6 mL). The solution was cooled in ice-water bath for 15 minutes. A stock solution of LiOH in water (35.4 mg/0.6 mL, 1.48 mmol) was added dropwise at 0° C. The mixture was warmed to room temperature (all precipitate dissolved) and stirred for 4 hours. Less than 1% of the starting material remained after checking by LCMS. About 10 g of ice was added to the reaction mixture and the temperature was decreased to 0° C. Aqueous HCl (1N, 1.6 mL) was added dropwise at 0° C. to adjust the pH of the reaction mixture to between 2 and 3.
  • Example 10 To a dry flask containing the compound synthesized in Example 10 was added anhydrous tetrahydrofuran (0.9 mL) and CH 2 Cl 2 (2.7 mL). The resulting solution was cooled in ice-water bath for 15 minutes. Acetic anhydride (42 ul, 0.444 mmol) and pyridine (18 ul, 0.222 mmol) were added at 0° C. Then the mixture was warmed to room temperature and stirred for 3.5 hours under N 2 . The reaction was monitored via LCMS. The reaction solution was diluted with ethyl acetate (30 mL) followed by washing with water (10 mL) and brine (10 mL) and drying over Na 2 SO 4 .
  • ethyl acetate 30 mL
  • Triphenylphosphine (474 mg, 1.81 mmol) and hexachloroethane (428 mg, 1.81 mmol) were added to a dry flask equipped with stir bar.
  • Anhydrous CH 2 Cl 2 (18.5 mL) was added and the resulting solution was cooled well in ice-water bath under N 2 .
  • Triethylamine (351 ul, 2.52 mmol) was added slowly to the solution, followed by stirring for 10 minutes at 0° C.
  • the solution of the compound synthesized in Example 11 160 mg, 0.180 mmol) in anhydrous CH 2 Cl 2 (9.5 mL) was added dropwise and the temperature was kept at 0° C. to 2° C. After addition, reaction mixture was stirred at 0° C.
  • a number of tumor cell lines representing breast, lung, colon, ovarian and prostate cancer as well as melanoma were assayed under standard growth conditions in presence of varying amounts of diazonamide A, a hydroxylated form of Compound J, Compound J, paclitaxel and vinblastine.
  • the results are graphed as the concentration that diminishes growth by a factor of two (GI 50 ) in FIG. 1 .
  • GI 50 concentration that diminishes growth by a factor of two
  • FIG. 2 Additional experiments testing the effect of Compound J and paclitaxel on the survival of PTX10ovarian tumor cell line are shown in FIG. 2 . Plotted against concentration added, these results show that Compound J is more effective than paclitaxel in lowering the percentage of cells surviving. In FIG. 2 , the circles represent Compound J and the diamonds represent paclitaxel.
  • Compound J was injected intravenously into mice containing xenograft tumors grown from MDA-MB-435 breast cancer cells.
  • the intratumoral concentration of Compound J was measured as a function of time. The results are shown in FIG. 3 .
  • the terminal half-life of this compound is 297.6 minutes
  • the area under the curve is 3010224 min*ng/ml
  • the volume of distribution is 2.9 l/kg.
  • Compound J is comparable to paclitaxel in inhibiting the growth of HCT116 xenografts and PC-3 xenografts.
  • FIG. 4A 20 mg/kg of Compound J administered IV slows tumor growth in a manner similar to paclitaxel at the same concentration.
  • the *'s represent control mice, the squares represent 5 mg/kg Compound J; the diamonds represent 20 mg/kg Compound J; and the slanted line represents 20 mg/kg paclitaxel.
  • paclitaxel and Compound J at similar concentrations give similar curves of growth inhibition.
  • four of 10 animals used in the study were free of tumors for over five months and experienced no weight loss.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
US11/591,016 2005-10-31 2006-10-31 Diazonamide A analog Expired - Fee Related US7538129B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/591,016 US7538129B2 (en) 2005-10-31 2006-10-31 Diazonamide A analog

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/264,502 US7517895B2 (en) 2001-08-24 2005-10-31 Synthetic diazonamides
US81465106P 2006-06-16 2006-06-16
US11/591,016 US7538129B2 (en) 2005-10-31 2006-10-31 Diazonamide A analog

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US11/264,502 Continuation-In-Part US7517895B2 (en) 2001-08-24 2005-10-31 Synthetic diazonamides

Publications (2)

Publication Number Publication Date
US20070149583A1 US20070149583A1 (en) 2007-06-28
US7538129B2 true US7538129B2 (en) 2009-05-26

Family

ID=38006479

Family Applications (1)

Application Number Title Priority Date Filing Date
US11/591,016 Expired - Fee Related US7538129B2 (en) 2005-10-31 2006-10-31 Diazonamide A analog

Country Status (8)

Country Link
US (1) US7538129B2 (enrdf_load_stackoverflow)
EP (1) EP1948169A4 (enrdf_load_stackoverflow)
JP (1) JP2009513710A (enrdf_load_stackoverflow)
AU (1) AU2006308849A1 (enrdf_load_stackoverflow)
BR (1) BRPI0618136A2 (enrdf_load_stackoverflow)
CR (1) CR10038A (enrdf_load_stackoverflow)
EA (1) EA013692B1 (enrdf_load_stackoverflow)
WO (1) WO2007053650A2 (enrdf_load_stackoverflow)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100022607A1 (en) * 2008-05-22 2010-01-28 Hanson Gunnar James Diazonamide analogs
US20120190862A1 (en) * 2007-06-07 2012-07-26 Hanson Gunnar Methods for Preparing Diazonamides
WO2012145255A2 (en) 2011-04-22 2012-10-26 Joyant Pharmaceuticals, Inc. Diazonamide analogs
US10353032B2 (en) * 2015-10-27 2019-07-16 Halliburton Energy Services, Inc. Viscosity determination apparatus, systems, and methods

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7960420B2 (en) * 2007-12-21 2011-06-14 Joyant Pharmaceuticals, Inc Diazonamide analogs with improved solubility
CA2720516C (en) * 2008-04-29 2013-10-01 Joyant Pharmaceuticals, Inc. Indoline anti-cancer agents

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030100589A1 (en) 2001-08-24 2003-05-29 Harran Patrick G. Synthetic diazonamides as novel anti-mitotic agents

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7517895B2 (en) * 2001-08-24 2009-04-14 Board Of Regents, The University Of Texas System Synthetic diazonamides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030100589A1 (en) 2001-08-24 2003-05-29 Harran Patrick G. Synthetic diazonamides as novel anti-mitotic agents
US7022720B2 (en) * 2001-08-24 2006-04-04 Board Of Regents, The University Of Texas System Synthetic diazonamides as novel anti-mitotic agents

Non-Patent Citations (39)

* Cited by examiner, † Cited by third party
Title
Bagley et al., "Studies toward the synthesis of diazonamide A. Synthesis of the 4-(oxazol-5-ylmethyl) aryltryptamine fragment," Tetrahedron Lett. (2000) 41:6901-6904.
Bagley et al., "Studies toward the synthesis of diazonamide A. Synthesis of the indole bis-oxazole flagment," Tetrahedron Lett. (2000) 41:6897-6900.
Belshaw et al., "Aminoacyl-CaAs as probes of condensation domain selectivity in nonribosomal pepetide synthesis," Science (1999) 284:486-489.
Belshaw et al., "Kinetics and regioselectivity of peptide-to-heterocycle conversions by microcin B17 synthetase," Chem. Biol. (1998) 5:373-84.
Boto et al., "A synthetic approach towards the aromatic macrocyclic core of Diazonamide A based on sp2-sp2 coupling protocols," Tetrahedron Lett. (1998) 39:8167-8170.
Chan et al., "Synthesis of the 4-arylindole portion of the antitumor agent diazonamide and related studies," Tetrahedron Lett. (2000) 41:835-838.
Cragg, "Natural products in drug discovery and development," J. Nat. Prod. (1997) 60:52-60.
Fuerst et al., "Synthesis of C(3) benzofuran-derived bisaryl quaternary centers: approaches to diazonamide A," Org. Lett. (2000) 2:3521-3523.
Gelfand and Bershadsky, "Microtubule dynamics: mechanism, regulation and function," Ann. Rev. Cell Biol. (1991) 7:93-116.
Hang et al., "The synthesis of 3-methoxylcarbonylbenzofuran-2(3H)-one derivatives via copper(I)-catalyzed coupling of o-bromophenols with dimethyl malonate," Synthesis (1999) 398-400.
Helene C. Vervoort, Ph.D. thesis, (1999) "Novel anticancer agents from Ascidiacea," University of California, San Diego (Scripps Institution of Oceanography).
International Search Report for PCT/US06/42565, mailed on Sep. 25, 2007, 2 pages.
Jeong et al., "Macrocyclic triarylethylenes via Heck endocyclization: A system relevant to diazonamide synthesis," J. Org. Chem. (1998) 63:8640-8641.
Kreisberg et al., "Vilsmeier methodology for the synthesis of 3-(2-N-phtaloylacyl)indole derivatives, and its application to the synthesis of the GCDEF rings of diazonamide," Tetrahedron Lett. (2001) 42:627-629.
Lach et al., "Studies towards the synthesis of diazonamide A. Synthesis of a tyrosine-derived benzofuranone," Tetrahedron Lett. (2000) 41:6893-6896.
Li et al., "Synthetic seco forms of(-)-Diazonamide A," Angew Chem. Int. Ed. (2001) 40:2683-2685.
Li et al., "Total synthesis of nominal diazonamides-Part 2: On the true structure and origin of natural isolates," Angew Chem. Int. Ed. (2001) 40:4770-4773.
Li et al., "Total synthesis of nominal diazonamides-Part I: Convergent preparation of the structure proposed for (-)-diazonamide A," Angew Chem. Int. Ed. (2001) 40:4765-4769.
Lindquist and Fenical, "Isolation and structure determination of Diazonamides A and B, unusual cytotoxic metabolites from the marine ascidian Diazona chinesis," J. Am. Chem. Soc. (1991) 113:2303-2304.
Lindquist, Ph.D. thesis, University of California San Diego, 1989.
Magnus et al., "Synthesis of benzofuranones related to Diazonamide via an intramolecular pummerer reaction," Tetrahedron Lett. (1999) 40:451-454.
Magnus et al., "Synthesis of the dichlorobisoxazole-indole portion of the antitumor agent diazonamide by a putatie biogenetic strategy," Tetrahedron Lett. (2000) 41:831-834.
Moody et al., "Studies toward the synthesis of Diazonamide A. Unexpected formation of a 3, 4-bridged indole," J. Chem. Soc. Perkin. Trans. (1996) 16:2413-2419.
Moody et al., "Synthesis of heterocyclic natural products: Model studies towards diazonamide A," Pure Appl. Chem. (1994) 66:2107-2110.
Negishi et al., "Reaction of zirconocene dichloride with alkylithiums or alkyl grignard reagents as convenient method for generating a 'zirconocene' equivalent and its use in zirconium-promoted cyclization of alkenes, alkynes, dienes, enynes and diynes," Tetrahedron Lett. (1986) 27:2829.
Nicolaou et al., "Construction of the complete aromatic core of diazonamide A by a novel hetero pinacol macrocyclic cascade reaction," Angew Chem. (2001) 113:4841-4845.
Nicolaou et al., "Construction of the complete aromatic core of diazonamide A by a novel hetero pinacol macrocyclic cascade reaction," Angew Chem. Int. Ed. (2001) 40:4705-4709.
Nicolaou et al., "Model studies towards Diazonamide A:synthesis of the heterocyclic core," Angew Chem. (2000) 112:3615-3620.
Nicolaou et al., "Model studies towards Diazonamide A:synthesis of the heterocyclic core," Angew Chem. Int. Ed. (2000) 39:3473-3478.
Ritter and Carreira, "The Diazonamides: The plot thickens," Angew Chem. Int. Ed. (2002) 41:2489-2495.
Shu, "Recent natural products based drug development: A pharmaceutical industry perspective," J. Nat. Prod. (1998) 61:1053-1071.
Takahashi et al., "Oxidative addition of 2-haloalkene to zirconocene," J. Am. Chem. Soc. (1995) 117:11039-11040.
Vedejs et al., "Atyrosin-derived benzofuranone related to Diazonamide A," Org. Lett. (200002:1031-1032.
Vedejs et al., "Progress toward synthesis of Diazonamide A. Preparation of a 3-(Oxazol-5-yl)-4-trfifluoromethyl-sulfonyloxylindole and its use in biaryl coupling reactions," Org. Lett. (2000) 2:1033-1035.
Vedejs et al., "Synthesis of the diazonamide core via a dieckmann-type cyclization," Org. Lett. (2001) 3:2451-2454.
Wilson, "Total synthesis suprise: Scientists revise structure of coveted anticancer marine natural product," Dec. 21, 2001, Chemical and Engineering News, 79:11.
Wipf et al., "Synthetic studies toward Diazonamide A. Preparation of the benzofuranone-indolyloxazole fragment," Tetrahedron Lett. (1998) 39:2223-2226.
Wipf et al., "Synthetic studies toward diazonamide A: a novel approach for polyoxazole synthesis," Org. Lett. (2001) 3:1261-1264.
Written Opinion of the International Searching Authority for PCT/US06/42565, mailed on Sep. 25, 2007, 5 pages.

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120190862A1 (en) * 2007-06-07 2012-07-26 Hanson Gunnar Methods for Preparing Diazonamides
US8299268B2 (en) * 2007-06-07 2012-10-30 Board Of Regents, The University Of Texas System Methods for preparing diazonamides
US20100022607A1 (en) * 2008-05-22 2010-01-28 Hanson Gunnar James Diazonamide analogs
US8153619B2 (en) * 2008-05-22 2012-04-10 Joyant Pharmaceuticals, Inc. Diazonamide analogs
WO2012145255A2 (en) 2011-04-22 2012-10-26 Joyant Pharmaceuticals, Inc. Diazonamide analogs
WO2012145255A3 (en) * 2011-04-22 2012-12-27 Joyant Pharmaceuticals, Inc. Diazonamide analogs
RU2608308C2 (ru) * 2011-04-22 2017-01-17 Джоянт Фармасьютикалс, Инк. Аналоги диазонамида
US10353032B2 (en) * 2015-10-27 2019-07-16 Halliburton Energy Services, Inc. Viscosity determination apparatus, systems, and methods

Also Published As

Publication number Publication date
AU2006308849A1 (en) 2007-05-10
US20070149583A1 (en) 2007-06-28
WO2007053650A3 (en) 2007-11-22
EA013692B1 (ru) 2010-06-30
BRPI0618136A2 (pt) 2011-08-16
CR10038A (es) 2008-09-12
EA200801238A1 (ru) 2008-12-30
WO2007053650A2 (en) 2007-05-10
JP2009513710A (ja) 2009-04-02
EP1948169A2 (en) 2008-07-30
EP1948169A4 (en) 2009-11-04

Similar Documents

Publication Publication Date Title
US11007181B2 (en) Cyclopamine analogs
US7538129B2 (en) Diazonamide A analog
CA3035989C (en) Amino mercaptan compound and preparation method therefor and use thereof in protection against radiation
ES2441115T3 (es) Derivados de CBI sujetos a activación reductora
KR19980703583A (ko) 아스코마이신
CA2836915A1 (en) Emetine derivatives, prodrugs containing same, and methods of treating conditions using same
KR101343443B1 (ko) 콜키친 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조 방법 및 이를 포함하는 약학 조성물
US8809549B2 (en) Esters of bendamustine and related compounds, and medical use thereof
JPH0755923B2 (ja) 医薬組成物
RU2450007C2 (ru) Производные камптотецина с противоопухолевой активностью
US11370766B2 (en) Sulfonyl amidine as indoleamine-2,3-dioxygenase inhibitor, and preparation method therefor and use thereof
TW201922690A (zh) 環－amp反應元素結合蛋白的抑制劑
JPH08509740A (ja) カンプトテシンの水溶性誘導体
KR20170073699A (ko) 신규한 유형의 시티딘 유도체 이량체 및 그의 용도
WO2019001307A1 (zh) 一种酰胺类化合物及包含该化合物的组合物及其用途
Aksinenko et al. 2-Propargylamino-6-(trifluoromethoxy) benzo [d] thiazoles in an alkyne-azide click reaction with pharmacologically active fragments
US20190365711A1 (en) Compound having anti-cancer effect, and preparation method therefor and use thereof
CA2628026A1 (en) Diazonamide a analog
US20200038371A1 (en) Compound having anticancer activity and preparation method and application
AU2019309942A1 (en) Derivatives of papaverine that are effective hypoxic tumor radiosensitizers
CN111499623B (zh) 一类非核苷抗肿瘤药物的噻唑酮脲衍生物及其药物用途
MX2008005646A (en) Diazonamide a analog
JP2019524654A (ja) 新しいタイプのタキサン化合物、その製造方法および適用
WO2023142803A1 (zh) 抗病毒化合物及其用途
WO2015103901A1 (zh) 硬脂酰氨基酸盐及其制备方法和应用

Legal Events

Date Code Title Description
AS Assignment

Owner name: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM,

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HARRAN, PATRICK G.;WILLIAMS, NOELLE;BURGETT, ANTHONY;REEL/FRAME:018969/0243;SIGNING DATES FROM 20070214 TO 20070220

AS Assignment

Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF

Free format text: CONFIRMATORY LICENSE;ASSIGNOR:UNIVERSITY OF TEXAS SW MEDICAL CENTER AT DALLAS;REEL/FRAME:021700/0153

Effective date: 20040611

CC Certificate of correction
FPAY Fee payment

Year of fee payment: 4

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20170526

AS Assignment

Owner name: NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR, MARYLAND

Free format text: CONFIRMATORY LICENSE;ASSIGNOR:UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER;REEL/FRAME:051567/0583

Effective date: 20200112

AS Assignment

Owner name: NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR, MA

Free format text: CONFIRMATORY LICENSE;ASSIGNOR:UT SOUTHWESTERN MEDICAL CENTER;REEL/FRAME:051536/0375

Effective date: 20200116